DOCSLIB.ORG

Transmission of Tropical and Geographically Restricted Infections During Solid-Organ Transplantation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Transmission of Tropical and Geographically Restricted Infections During Solid-Organ Transplantation CLINICAL MICROBIOLOGY REVIEWS, Jan. 2008, p. 60–96 Vol. 21, No. 1 0893-8512/08/$08.00ϩ0 doi:10.1128/CMR.00021-07 Copyright © 2008, American Society for Microbiology. All Rights Reserved. Transmission of Tropical and Geographically Restricted Infections during Solid-Organ Transplantation P. Martı´n-Da´vila,1,2* J. Fortu´n,1,2 R. Lo´pez-Ve´lez,1,3 F. Norman,3 M. Montes de Oca,3 P. Zamarro´n,3 M. I. Gonza´lez,3 A. Moreno,4 T. Pumarola,5 G. Garrido,6 A. Candela,7 and S. Moreno1 Infectious Diseases Department, Ramon y Cajal Hospital, Madrid, Spain1; Transplant Infectious Diseases Team, Ramon y Cajal Hospital, Madrid, Spain2; Tropical and Travel Medicine Unit, Ramon y Cajal Hospital, Madrid, Spain3; Infectious Diseases Department, Clinic Hospital, Barcelona, Spain4; Microbiology Department, Clinic Hospital, Barcelona, Spain5; Spanish Transplantation Network, Madrid, Spain6; and Anaesthesiology Department, Transplant Program, Ramon y Cajal Hospital, Madrid, Spain7 INTRODUCTION .........................................................................................................................................................62 Tropical and Geographically Restricted Infectious Diseases and Organ Transplantation ...........................62 VIRAL INFECTIONS...................................................................................................................................................63 Infections Caused by HTLV-1/2..............................................................................................................................63 Illnesses..................................................................................................................................................................63 (i) ATL................................................................................................................................................................63 (ii) TSP...............................................................................................................................................................63 Geographic distribution .......................................................................................................................................63 Diagnostic methods ..............................................................................................................................................63 Routes of transmission.........................................................................................................................................65 Transplant-related cases......................................................................................................................................66 (i) Seroprevalence .............................................................................................................................................66 (ii) Type of organ transplanted, exposure to blood transfusions, and viral characteristics..................66 (iii) Influence of immunosuppression............................................................................................................66 Recommendations .................................................................................................................................................67 Infections Caused by West Nile Virus ...................................................................................................................67 Geographic distribution .......................................................................................................................................67 Diagnostic methods ..............................................................................................................................................68 Routes of transmission.........................................................................................................................................68 Transplant-related cases......................................................................................................................................68 Recommendations .................................................................................................................................................68 Infections Caused by Rabies Virus.........................................................................................................................69 Geographic distribution .......................................................................................................................................69 Diagnostic methods ..............................................................................................................................................69 Routes of transmission.........................................................................................................................................69 Transplant-related cases......................................................................................................................................70 Recommendations .................................................................................................................................................70 FUNGAL INFECTIONS ..............................................................................................................................................70 Infections Caused by Coccidioides immitis .............................................................................................................70 Geographic distribution .......................................................................................................................................70 Diagnostic methods ..............................................................................................................................................70 Routes of transmission.........................................................................................................................................71 Transplant-related cases......................................................................................................................................71 Recommendations .................................................................................................................................................71 Infections Caused by Histoplasma capsulatum.......................................................................................................72 Geographic distribution .......................................................................................................................................72 Diagnostic methods ..............................................................................................................................................72 Routes of transmission.........................................................................................................................................72 Transplant-related cases......................................................................................................................................72 Recommendations .................................................................................................................................................73 * Corresponding author. Mailing address: Servicio de Enfermedades Infecciosas, Hospital Ramo´n y Cajal, Ctra. Colmenar km. 9,100, 28034 Madrid, Spain. Phone: 34 913368710. Fax: 34 913368792. E-mail: pmartin [email protected]. 60 VOL. 21, 2008 TRANSMISSION OF INFECTIONS DURING SOLID-ORGAN TRANSPLANT 61 Other Regional Fungal Infections ..........................................................................................................................73 Infections caused by Paracoccidioides brasiliensis .............................................................................................73 Infections caused by Blastomyces dermatitidis....................................................................................................73 Infections caused by Penicillium marneffei ..............................................................................................74 PARASITIC INFECTIONS .........................................................................................................................................74 Infections Caused by Plasmodium spp. ..................................................................................................................74 Geographic distribution .......................................................................................................................................74 Diagnostic methods ..............................................................................................................................................74 Routes of transmission.........................................................................................................................................75 Transplant-related cases......................................................................................................................................75 Recommendations .................................................................................................................................................75 Infections Caused by Leishmania spp. ...................................................................................................................76 Geographic distribution .......................................................................................................................................76
Load more

Recommended publications
  • (Sporanox Capsules) 280-A
    PRIOR AUTHORIZATION CRITERIA BRAND NAME (generic) SPORANOX ORAL CAPSULES (itraconazole) Status: CVS Caremark Criteria Type: Initial Prior Authorization Policy FDA-APPROVED INDICATIONS Sporanox (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: 1. Blastomycosis, pulmonary and extrapulmonary 2. Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and 3. Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Sporanox Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: 1. Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and 2. Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. Compendial Uses Coccidioidomycosis2,3
    [Show full text]
  • HIV Infection and AIDS
    G Maartens 12 HIV infection and AIDS Clinical examination in HIV disease 306 Prevention of opportunistic infections 323 Epidemiology 308 Preventing exposure 323 Global and regional epidemics 308 Chemoprophylaxis 323 Modes of transmission 308 Immunisation 324 Virology and immunology 309 Antiretroviral therapy 324 ART complications 325 Diagnosis and investigations 310 ART in special situations 326 Diagnosing HIV infection 310 Prevention of HIV 327 Viral load and CD4 counts 311 Clinical manifestations of HIV 311 Presenting problems in HIV infection 312 Lymphadenopathy 313 Weight loss 313 Fever 313 Mucocutaneous disease 314 Gastrointestinal disease 316 Hepatobiliary disease 317 Respiratory disease 318 Nervous system and eye disease 319 Rheumatological disease 321 Haematological abnormalities 322 Renal disease 322 Cardiac disease 322 HIV-related cancers 322 306 • HIV INFECTION AND AIDS Clinical examination in HIV disease 2 Oropharynx 34Neck Eyes Mucous membranes Lymph node enlargement Retina Tuberculosis Toxoplasmosis Lymphoma HIV retinopathy Kaposi’s sarcoma Progressive outer retinal Persistent generalised necrosis lymphadenopathy Parotidomegaly Oropharyngeal candidiasis Cytomegalovirus retinitis Cervical lymphadenopathy 3 Oral hairy leucoplakia 5 Central nervous system Herpes simplex Higher mental function Aphthous ulcers 4 HIV dementia Kaposi’s sarcoma Progressive multifocal leucoencephalopathy Teeth Focal signs 5 Toxoplasmosis Primary CNS lymphoma Neck stiffness Cryptococcal meningitis 2 Tuberculous meningitis Pneumococcal meningitis 6
    [Show full text]
  • Bacterial and Parasitic Infection of the Liver with Sebastian Lucas
    Bacterial & parasitic infections Sebastian Lucas Dept of Histopathology St Thomas’ Hospital London SE1 Post-Tx infections Hepatitis A-x EBV HBV HCV Biliary tract infections HIV disease Crypto- sporidiosis CMV Other viral infections Bacterial & Parasitic infections Liver Hepatobiliary parasites • Leishmania spp • Trypanosoma cruzi • Entamoeba histolytica Biliary tree & GB • Toxoplasma gondii • microsporidia spp • Plasmodium falciparum • Balantidium coli • Cryptosporidium spp • Strongyloides stercoralis • Ascaris • Angiostrongylus spp • Fasciola hepatica • Enterobius vermicularis • Ascaris lumbricoides • Clonorchis sinensis • Baylisascaris • Opisthorcis viverrini • Toxocara canis • Dicrocoelium • Gnathostoma spp • Capillaria hepatica • Echinococcus granulosus • Schistosoma spp • Echinococcus granulosus & multilocularis Gutierrez: ‘Diagnostic Pathology of • pentasomes Parasitic Infections’, Oxford, 2000 What is this? Both are the same parasite What is this? Both are the same parasite Echinococcus multilocularis Bacterial infections of liver and biliary tree • Chlamydia trachomatis • Gram-ve rods • Treponema pallidum • Neisseria meningitidis • Borrelia spp • Yersina pestis • Leptospira spp • Streptococcus milleri • Mycobacterium spp • Salmonella spp – tuberculosis • Burkholderia pseudomallei – avium-intracellulare • Listeria monocytogenes – leprae • Brucella spp • Bartonella spp Actinomycetes • In ‘MacSween’ 2 manifestations of a classic bacterial infection Bacteria & parasites What you need to know 3 case studies • What can happen – differential
    [Show full text]
  • PRIOR AUTHORIZATION CRITERIA BRAND NAME (Generic) SPORANOX ORAL CAPSULES (Itraconazole)
    PRIOR AUTHORIZATION CRITERIA BRAND NAME (generic) SPORANOX ORAL CAPSULES (itraconazole) Status: CVS Caremark Criteria Type: Initial Prior Authorization Policy FDA-APPROVED INDICATIONS Sporanox (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: 1. Blastomycosis, pulmonary and extrapulmonary 2. Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and 3. Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Sporanox Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: 1. Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and 2. Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. Compendial Uses Coccidioidomycosis2,3
    [Show full text]
  • Microsporidiosis in Vertebrate Companion Exotic Animals
    Review Microsporidiosis in Vertebrate Companion Exotic Animals Claire Vergneau-Grosset 1,*,† and Sylvain Larrat 2,† Received: 13 October 2015; Accepted: 18 December 2015; Published: 24 December 2015 Academic Editor: Zhi-Yuan Chen 1 Zoological medicine service, Faculté de médecine vétérinaire, Université de Montréal, 3200 Sicotte, Saint-Hyacinthe, QC J2S2M2, Canada 2 Clinique Vétérinaire Benjamin Franklin, 38 rue du Danemark, ZA Porte Océane, 56400 Brech, France; [email protected] * Correspondence: [email protected]; Tel.: +1-450-773-8521 (ext. 16079) † These authors contributed equally to this work. Abstract: Veterinarians caring for companion animals may encounter microsporidia in various host species, and diagnosis and treatment of these fungal organisms can be particularly challenging. Fourteen microsporidial species have been reported to infect humans and some of them are zoonotic; however, to date, direct zoonotic transmission is difficult to document versus transit through the digestive tract. In this context, summarizing information available about microsporidiosis of companion exotic animals is relevant due to the proximity of these animals to their owners. Diagnostic modalities and therapeutic challenges are reviewed by taxa. Further studies are needed to better assess risks associated with animal microsporidia for immunosuppressed owners and to improve detection and treatment of infected companion animals. Keywords: microsporidia; Encephalitozoon; Pleistophora; albendazole; fenbendazole 1. Introduction Microsporidia are eukaryotic organisms with the smallest known genome [1]. Microsporidia had been classified as amitochondriate due to their lack of visible mitochondria, but sequences homologous to genes coding for mitochondria have since been discovered in their genome and remnants of mitochondria have been visualized in their cytoplasm [2]; therefore, they have been reclassified as fungi based on phylogenic analysis of multiple proteins in their genome, clustering preferentially with fungal proteins [2,3].
    [Show full text]
  • A Possible Role for Fumagillin in Cellular Damage During Host
    VIRULENCE 2018, VOL. 9, NO. 1, 1548–1561 https://doi.org/10.1080/21505594.2018.1526528 RESEARCH PAPER A possible role for fumagillin in cellular damage during host infection by Aspergillus fumigatus Xabier Guruceaga a, Guillermo Ezpeleta b,c, Emilio Mayayod, Monica Sueiro-Olivaresa, Ana Abad-Diaz-De- Cerio a, José Manuel Aguirre Urízar e, Hong G. Liuf,g, Philipp Wiemann h, Jin Woo Bokh, Scott G. Filler f,g, Nancy P. Keller h,i, Fernando L. Hernandoa, Andoni Ramirez-Garcia a, and Aitor Rementeria a aFungal and Bacterial Biomics Research Group, Department of Immunology, Microbiology and Parasitology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Spain; bPreventive Medicine and Hospital Hygiene Service, Complejo Hospitalario de Navarra, Pamplona, Spain; cDepartment of Preventive Medicine and Public Health, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain; dPathology Unit, Medicine and Health Science Faculty, University of Rovira i Virgili, Reus, Tarragona, Spain; eDepartment of Stomatology II, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain; fDivision of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA; gDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; hDepartment of Medical Microbiology and Immunology, University of Wisconsin, Madison, WI, USA; iDepartment of Bacteriology, University of Wisconsin, Madison, WI, USA ABSTRACT ARTICLE HISTORY Virulence mechanisms of the pathogenic fungus Aspergillus fumigatus are multifactorial and Received 28 March 2018 depend on the immune state of the host, but little is known about the fungal mechanism that Accepted 10 September develops during the process of lung invasion.
    [Show full text]
  • Opportunistic Protozoan Infections in Human
    182 J Clin Pathol 1991;44:182-193 Opportunistic protozoan infections in human immunodeficiency virus disease: Review J Clin Pathol: first published as 10.1136/jcp.44.3.182 on 1 March 1991. Downloaded from highlighting diagnostic and therapeutic aspects A Curry, A J Turner, S Lucas Introduction AIDS. The AIDS epidemic has considerably Opportunistic protozoan infections are among increased our awareness of this organism, the most serious infections in patients with which is now known to be a common child- AIDS."A They cause severe morbidity and hood infection among the immunocompetent mortality; because many are treatable, it is in whom the infection is self-limiting.8 In important that early and accurate diagnoses patients with AIDS and in other immuno- are made. This is normally accomplished by compromised groups infection can be both direct microscopic visualisation of the parasite protracted and life threatening. It has a par- in infected tissues or body secretions. Rigid ticularly high incidence in HIV positive adherence to normal diagnostic procedures patients with diarrhoea in Africa" and it is may not be appropriate in patients with AIDS found in up to 10% of most series of HIV because the site and manifestation of some of positive patients with diarrhoea in the United these infections may be unusual. Experience Kingdom and the United States of America. of these conditions among histopathologists The gastrointestinal tract from oesophagus to and microbiologists is extremely variable. rectum, the biliary tract including intra- Furthermore, treatment of the protozoan hepatic ducts, and the bronchial tree can be infections in patients with AIDS is often com- infected in patients with AIDS.'2"3 Infection plicated by severe side effects and a high rate is caused by the ingestion of oocysts in food or of recurrence.
    [Show full text]
  • Infection Control for Instruments
    Infection Control for Instruments by ShelB Rindahl with Laurel Partin & Christina Colston hosted by Acknowledgements & Disclaimer Most heartfelt thanks to: Eastman Music Company, for hosting the introductory video series, for graphic design support, and for housing the literature online, in perpetuity, for free public use. Without Eastman, ICI would not have been as inclusive or as accessible to all those who need it. Key members of Eastman’s team were Meagan Dolce, who hosted the webinars and managed the web migration, as well as Chad Archibald, Abigail Brooks, and Beau Foster, who built the online resources and provided graphic design support. The National Association of Professional Band Instrument Repair Technicians (NAPBIRT), for the platform that first shared ICI, and for their long-time commitment to the professional development of instrument repairers, including the creator of ICI and all of its contributors. Without NAPBIRT, and the strong mentorship of its members, ICI would not have been inspired or developed in this way. Our test readers, Christina Colston, Meagan Dolce, Jessica Ganska, Kim Jurens, Reese Mandeville, Yvonne Rodriguez, and Steven Thompson, who suffered long hours and many revisions to make sense of our translations. Our families, friends, and colleagues, who made suggestions for content or organization, and who offered tremendous strength and tireless support along the way. Disclaimer: Infection Control for Instruments (ICI) is offered in good faith, but reader and user discretion are advised. The ICI team, our hosts, and our presenters, do not assume liability for decisions or actions of readers and users. ICI is not written or approved by licensed medical practitioners or infection control specialists and is not peer-reviewed.
    [Show full text]
  • Fungi from a Groundwater-Fed Drinking Water Supply System in Brazil
    International Journal of Environmental Research and Public Health Article Fungi from a Groundwater-Fed Drinking Water Supply System in Brazil Helena M.B. Oliveira 1, Cledir Santos 2, R. Russell M. Paterson 3, Norma B. Gusmão 1 and Nelson Lima 3,* 1 Department of Antibiotics, Federal University of Pernambuco, Av. Prof. Morais Rego, 1235, Recife, Pernambuco 50670-901, Brazil; [email protected] (H.M.B.O.); [email protected] (N.B.G.) 2 Department of Chemical Sciences and Natural Resources, BIOREN-UFRO Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco 4811-230, Chile; [email protected] 3 Centre of Biological Engineering, University of Minho, Campus de Gualtar, Braga 4710-057, Portugal; [email protected] * Correspondence: [email protected]; Tel.: +351-253-604-403 Academic Editor: Panagiotis Karanis Received: 11 February 2016; Accepted: 4 March 2016; Published: 9 March 2016 Abstract: Filamentous fungi in drinking water distribution systems are known to (a) block water pipes; (b) cause organoleptic biodeterioration; (c) act as pathogens or allergens and (d) cause mycotoxin contamination. Yeasts might also cause problems. This study describes the occurrence of several fungal species in a water distribution system supplied by groundwater in Recife—Pernambuco, Brazil. Water samples were collected from four sampling sites from which fungi were recovered by membrane filtration. The numbers in all sampling sites ranged from 5 to 207 colony forming units (CFU)/100 mL with a mean value of 53 CFU/100 mL. In total, 859 isolates were identified morphologically, with Aspergillus and Penicillium the most representative genera (37% and 25% respectively), followed by Trichoderma and Fusarium (9% each), Curvularia (5%) and finally the species Pestalotiopsis karstenii (2%).
    [Show full text]
  • Disseminated Microsporidiosis Caused By
    Disseminated Microsporidiosis Caused by Encephalitozoon cuniculi III (Dog Type) in an Italian AIDS Patient: a Retrospective Study Antonella Tosoni, B.Sc., Manuela Nebuloni, M.D., Angelita Ferri, M.D., Sara Bonetto, M.D., Spinello Antinori, M.D., Massimo Scaglia, M.D., Lihua Xiao, D.V.M., Ph.D., Hercules Moura, M.D., Ph.D., Govinda S. Visvesvara, Ph.D., Luca Vago, M.D., Giulio Costanzi, M.D. Pathology Unit, “L.Sacco” Hospital and Institute of Biomedical Sciences, University of Milan, Italy (AT, AF, SB, LV, GC); Institute of Infectious Diseases and Tropical Medicine, University of Milan, “L. Sacco” Hospital, Milan, Italy (SA); Pathology Unit, Hospital of Vimercate, Milan, Italy (MN); Infectious Diseases Research Laboratories and Department of Infectious Diseases, University of Pavia—IRCCS, San Matteo, Italy (MS); and Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, Atlanta, Georgia (LX, GSV, HM) The prevalence of opportunistic microsporidial We report a case of disseminated microsporidiosis infections in humans greatly increased during the in an Italian woman with AIDS. This study was done AIDS pandemia, particularly before the advent of retrospectively using formalin-fixed, paraffin- HAART. At least 12 species, belonging to seven gen- embedded tissue specimens obtained at autopsy. era (Enterocytozoon, Encephalitozoon, Pleistophora, Microsporidia spores were found in the necrotic Trachipleistophora, Brachiola, Nosema,andVit- lesions of the liver, kidney, and adrenal gland and in taforma), have been identified. Additionally, a ovary, brain, heart, spleen, lung, and lymph nodes. catch-all genus, Microsporidium, of uncertain The infecting agent was identified as belonging to taxonomic status, is also known to infect humans the genus Encephalitozoon based on transmission (2, 3).
    [Show full text]
  • Review Articles Parasitic Diseases and Fungal Infections
    Wiadomoœci Parazytologiczne 2011, 57(4), 205–218 Copyright© 2011 Polish Parasitological Society Review articles Parasitic diseases and fungal infections – their increasing importance in medicine 1 Joanna Błaszkowska, Anna Wójcik Chair of Biology and Medical Parasitology, Medical University of Lodz, 1 Hallera Square, 90-647 Lodz, Poland Corresponding author: Joanna Błaszkowska; E-mail: [email protected] ABSTRACT. Basing on 43 lectures and reports from the scope of current parasitological and mycological issues presented during the 50th Jubilee Clinical Day of Medical Parasitology (Lodz, 19–20 May 2011), the increasing importance of parasitic diseases and mycoses in medicine was presented. Difficulties in diagnosis and treatment of both imported parasitoses (malaria, intestinal amoebiosis, mansonelliasis) and native parasitoses (toxoplasmosis, toxocariasis, CNS cysticercosis), as well as parasitic invasions coexisting with HIV infection (microsporidiosis) have been emphasized. The possibility of human parasites transmission by vertical route and transfusion has been discussed. The important issue of diagnostic problems in intestinal parasitoses has been addressed, noting the increasing use of immunoenzymatic methods which frequently give false positive results. It was highlighted that coproscopic study is still the reference method for detecting parasitic intestinal infections. The mechanism of the immune reaction induced by intestinal nematodes resulting in, among others, inhibition of the host innate and acquired response was presented. Mycological topics included characteristics of various clinical forms of mycoses (central nervous system, oral cavity and pharynx, paranasal sinuses, nails and skin), still existing problem of antimicrobial susceptibility of fungal strains, diagnostic and therapeutic difficulties of zoonotic mycoses and the importance of environmental factors in pathogenesis of mycosis.
    [Show full text]
  • Microsporidiosis (Last Updated December 15, 2016; Last Reviewed December 15, 2016)
    Microsporidiosis (Last updated December 15, 2016; last reviewed December 15, 2016) Panel’s Recommendations I. In children with HIV infection, what are the best interventions (compared with no intervention) to treat microsporidiosis? • Effective antiretroviral therapy (ART) is the primary initial treatment for microsporidiosis in HIV-infected children (strong, very low). • Supportive care with hydration, correction of electrolyte abnormalities, and nutritional supplementation should be provided (expert opinion). • Albendazole, in addition to ART, is also recommended for initial therapy of microsporidiosis caused by microsporidia other than Enterocytozoon bieneusi and Vittaforma corneae (strong, low). • Systemic fumagillin (where available), in addition to ART, is recommended for microsporidiosis caused by E. bieneusi and V. corneae (strong, moderate). • Topical therapy with fumagillin eye drops, in addition to ART, is recommended in HIV-infected children with keratoconjunctivitis caused by microsporidia (strong, very low). • Oral albendazole can be considered in addition to topical therapy for keratoconjunctivitis due to microsporidia other than E. bieneusi and V. corneae (expert opinion). II. In HIV-infected children who have been treated for microsporidiosis, when can treatment (secondary prophylaxis) be safely discontinued? Clinicians may consider continuing treatment for microsporidiosis until improvement in severe immunosuppression is sustained (more than 6 months at Centers for Disease Control and Prevention immunologic category 1 or 2) and clinical signs and symptoms of infection are resolved (weak, very low). Rating System: Strength of Recommendation: Strong, weak Quality of Evidence: High; Moderate; Low; or Very Low Introduction/Overview Epidemiology Microsporidia are obligate, intracellular, spore-forming organisms that primarily cause moderate to severe diarrhea. They are ubiquitous and infect most animal species.
    [Show full text]